Clinical Trial Update: Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam [Phase 3]

View source ↗

Summary

Phase IIIb, open-label, multicenter study evaluating the safety, tolerability, and efficacy of intrathecal OAV101 in spinal muscular atrophy patients who discon…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• OAV101

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Spinal Muscular Atrophy | Phase 3 | Status: COMPLETED | Results posted: 2025-06-03